Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

BACKGROUND: Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Lancet Oncol
Main Authors: Rizvi, Naiyer A, Mazières, Julien, Planchard, David, Stinchcombe, Thomas E, Dy, Grace K, Antonia, Scott J, Horn, Leora, Lena, Hervé, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A, Campos, Luis T, Gandara, David R, Levy, Benjamin P, Nair, Suresh G, Zalcman, Gérard, Wolf, Jürgen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M, Harbison, Christopher T, Baudelet, Christine, Lestini, Brian J, Ramalingam, Suresh S
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2015
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5726228/
https://ncbi.nlm.nih.gov/pubmed/25704439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)70054-9
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla